Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease
dc.contributor.author | Lerner, Gary | en_US |
dc.contributor.author | Heatherington, Anne | en_US |
dc.contributor.author | Bunchman, Timothy E. | en_US |
dc.contributor.author | Olson, Kurt | en_US |
dc.contributor.author | Maroni, Bradley J. | en_US |
dc.contributor.author | Warady, Bradley A. | en_US |
dc.contributor.author | Jabs, Kathy | en_US |
dc.contributor.author | Messer-Mann, Louise | en_US |
dc.contributor.author | Kale, Arundhati S. | en_US |
dc.date.accessioned | 2006-09-08T20:11:53Z | |
dc.date.available | 2006-09-08T20:11:53Z | |
dc.date.issued | 2002-11 | en_US |
dc.identifier.citation | Lerner, Gary; Kale, Arundhati S.; Warady, Bradley A.; Jabs, Kathy; Bunchman, Timothy E.; Heatherington, Anne; Olson, Kurt; Messer-Mann, Louise; Maroni, Bradley J.; (2002). "Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease." Pediatric Nephrology 17(11): 933-937. <http://hdl.handle.net/2027.42/42306> | en_US |
dc.identifier.issn | 0931-041X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42306 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12432437&dopt=citation | en_US |
dc.description.abstract | Darbepoetin alfa is a novel erythropoiesis-stimulating protein with a two- to threefold longer half-life than recombinant human erythropoietin (epoetin) in adult patients with chronic kidney disease (CKD). This randomized, open-label, crossover study was conducted to determine the pharmacokinetic profile of darbepoetin alfa in pediatric patients with CKD. Twelve patients 3–16 years of age with CKD were randomized and received a single 0.5 µg/kg dose of darbepoetin alfa administered intravenously (IV) or subcutaneously (SC). After a 14- to 16-day washout period, patients received an identical dose of darbepoetin alfa by the alternate route. After IV administration, the mean clearance of darbepoetin alfa was 2.3 ml/h per kg, with a mean terminal half-life of 22.1 h. After SC administration, absorption was rate limiting, with a mean terminal half-life of 42.8 h and a mean bioavailability of 54%. Comparison of these results with those from a previous study of darbepoetin alfa in adult patients indicated that the disposition of darbepoetin alfa administered IV or SC is similar in adult and pediatric patients, although absorption may be slightly more rapid in pediatric patients after SC dosing. The mean terminal half-life of darbepoetin alfa in this study was approximately two- to fourfold longer than that previously reported for epoetin in pediatric patients. | en_US |
dc.format.extent | 177583 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; IPNA | en_US |
dc.subject.other | Darbepoetin Alfa Novel Erythropoiesis-stimulating Protein Pharmacokinetics Anemia Chronic Kidney Disease | en_US |
dc.subject.other | Legacy | en_US |
dc.title | Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, Michigan, USA, | en_US |
dc.contributor.affiliationother | Baylor College of Medicine, Houston, Texas, USA, | en_US |
dc.contributor.affiliationother | Children's Mercy Hospital, Kansas City, Missouri, USA, | en_US |
dc.contributor.affiliationother | Division of Nephrology, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA, | en_US |
dc.contributor.affiliationother | Amgen, Thousand Oaks, California, USA, | en_US |
dc.contributor.affiliationother | Amgen, Thousand Oaks, California, USA, | en_US |
dc.contributor.affiliationother | Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, | en_US |
dc.contributor.affiliationother | Amgen, Thousand Oaks, California, USA, | en_US |
dc.contributor.affiliationother | Amgen, Thousand Oaks, California, USA, | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 12432437 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42306/1/s00467-002-0932-0.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s00467-002-0932-0 | en_US |
dc.identifier.source | Pediatric Nephrology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.